Latest News in the pharma Industry

Policy & Regulation

US ahead of Canada & Europe in Drug Approvals

US ahead of Canada & Europe in Drug Approvals

22 May 2012

A study has found that US FDA generally approves drugs faster and earlier than its counterparts in Canada and Europe.

Read more 
FDA Issues Warning over CCSVI Treatment

FDA Issues Warning over CCSVI Treatment

15 May 2012

The FDA is notifying physicians and clinical investigators who are planning or conducting clinical trials using medical devices to treat CCSVI that they must comply with FDA regulations for investigational devices.

Read more 
US Appeals Court Upholds Abilify Patent

US Appeals Court Upholds Abilify Patent

14 May 2012

Otsuka Pharmaceutical's antipsychotic drug Abilify is protected until April 2015, preventing generic versions of the drug from being launched until that time, a US court has ruled.

Read more 
FDA Committee Votes in Favour of Quad Approval

FDA Committee Votes in Favour of Quad Approval

14 May 2012

Gilead Sciences has announced that a US FDA committee has voted to support the approval of the Quad regimen and Truvada.

Read more 
FDA & EMA Approve Genzyme  Filling & Finishing Suite

FDA & EMA Approve Genzyme Filling & Finishing Suite

7 May 2012

With this approval, Genzyme has nearly doubled its ability to fill and finish Myozyme and Lumizyme produced at the 4000 liter bioreactor scale.

Read more 
EMA Recommends Authorisation of Forxiga for Type 2 Diabetes

EMA Recommends Authorisation of Forxiga for Type 2 Diabetes

25 Apr 2012

The Agency’s Committee for Medicinal Products for Human Use has recommended the granting of a marketing authorisation for Forxiga, a novel treatment for type 2 diabetes mellitus.

Read more 
Merck Wins Fifth Fosamax State Court Trial

Merck Wins Fifth Fosamax State Court Trial

23 Apr 2012

Merck says it has won its latest lawsuit connected to osteoporosis drug Fosamax.

Read more 
Johnson & Johnson Fined $1.1B for Concealing Risperdal Risks

Johnson & Johnson Fined $1.1B for Concealing Risperdal Risks

18 Apr 2012

Johnson & Johnson has been ordered to pay $1.1 billion for failing to make clear the risks associated with its anti-psychotic drug Risperdal.

Read more 
EMA Publishes New Document on Regulatory Procedural Advice on similar Biological Medicines

EMA Publishes New Document on Regulatory Procedural Advice on similar Biological Medicines

18 Apr 2012

The Agency has published a new document on regulatory procedural advice on similar biological medicines.

Read more 
NICE Rejects Halaven for Breast Cancer Treatment

NICE Rejects Halaven for Breast Cancer Treatment

5 Apr 2012

UK's National Insitiute for Clinical Excellence has rejected Eisai's Halaven for the treatment of advanced or metastatic breast cancer in people whose disease has progressed after at least two chemotherapeutic regimens.

Read more 
Brazil Tightens Gelatin Production Controls

Brazil Tightens Gelatin Production Controls

30 Mar 2012

The Brazilian government is tightening its gelatin production controls after pressure from the EU about consumer health concerns.

Read more 
Byetta Approved for Use with Basal Insulin in Europe

Byetta Approved for Use with Basal Insulin in Europe

26 Mar 2012

Amylin and Eli Lilly announced the marketing authorization from the European Commission for the use of BYETTA with basal insulin.

Read more